Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $6 to $7.

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.

Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focused on discovering, d...

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.7...

Capital One analyst Naureen Quibria initiates coverage on Erasca (NASDAQ:ERAS) with a Overweight rating and announces Price ...

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initia...

B of A Securities analyst Alec Stranahan downgrades Erasca (NASDAQ:ERAS) from Buy to Neutral and lowers the price target fro...

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence ...